TrialDiff
TrialDiff turns ClinicalTrials.gov amendment history into citeable evidence records: exact changed paths, source hashes, deterministic rules, timing context, and explicit claims-supported / claims-not-supported boundaries.
v0.1.3 · Corpus snapshot through 2026-05-22 · rule set fc87f4f0a74b
| Trial | Sponsor | Patches | Critical triage | High triage | Critical-triage density |
|---|---|---|---|---|---|
| NCT00769379 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy | National Cancer Institute (NCI) | 1,650 | 2 | 29 | 0.12%
critical-triage events / patches |
| NCT01275677 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | National Cancer Institute (NCI) | 979 | 2 | 23 | 0.20%
critical-triage events / patches |
| NCT00490139 ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D | Novartis Pharmaceuticals | 202 | 7 | 18 | 3.47%
critical-triage events / patches |
| NCT01124695 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer | ECOG-ACRIN Cancer Research Group | 131 | 0 | 5 | 0.00%
critical-triage events / patches |
| NCT01224678 Vitamin D and Breast Cancer Biomarkers in Female Patients | Alliance for Clinical Trials in Oncology | 111 | 1 | 5 | 0.90%
critical-triage events / patches |
| NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Bayer | 96 | 6 | 8 | 6.25%
critical-triage events / patches |
| NCT00099437 Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. | AstraZeneca | 68 | 1 | 9 | 1.47%
critical-triage events / patches |
| NCT02340221 A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy | Hoffmann-La Roche | 63 | 1 | 7 | 1.59%
critical-triage events / patches |
| NCT01142401 Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | National Cancer Institute (NCI) | 53 | 4 | 4 | 7.55%
critical-triage events / patches |
| NCT04482309 A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | AstraZeneca | 51 | 2 | 4 | 3.92%
critical-triage events / patches |
| NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | Bolt Biotherapeutics, Inc. | 34 | 3 | 5 | 8.82%
critical-triage events / patches |
| NCT02614833 IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma | Immutep S.A.S. | 34 | 1 | 5 | 2.94%
critical-triage events / patches |
| NCT03734029 Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | Daiichi Sankyo | 32 | 2 | 5 | 6.25%
critical-triage events / patches |
| NCT05415215 A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer | Hoffmann-La Roche | 32 | 0 | 5 | 0.00%
critical-triage events / patches |
| NCT01730833 Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | City of Hope Medical Center | 30 | 1 | 10 | 3.33%
critical-triage events / patches |
| NCT01556243 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer | Alliance for Clinical Trials in Oncology | 30 | 1 | 4 | 3.33%
critical-triage events / patches |
| NCT04569747 A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer | Dana-Farber Cancer Institute | 30 | 0 | 4 | 0.00%
critical-triage events / patches |
| NCT01471106 Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer | M.D. Anderson Cancer Center | 29 | 2 | 10 | 6.90%
critical-triage events / patches |
| NCT00530868 Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer | University of Alabama at Birmingham | 27 | 0 | 9 | 0.00%
critical-triage events / patches |
| NCT03025035 Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer | Yuan Yuan | 25 | 2 | 10 | 8.00%
critical-triage events / patches |
| NCT03584009 A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy | Hoffmann-La Roche | 25 | 2 | 4 | 8.00%
critical-triage events / patches |
| NCT02086578 Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions | Memorial Sloan Kettering Cancer Center | 24 | 0 | 11 | 0.00%
critical-triage events / patches |
| NCT02154529 Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | Kadmon Corporation, LLC | 24 | 3 | 7 | 12.50%
critical-triage events / patches |
| NCT03414684 Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer | Dana-Farber Cancer Institute | 23 | 2 | 3 | 8.70%
critical-triage events / patches |
| NCT04478279 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Sapience Therapeutics | 23 | 0 | 4 | 0.00%
critical-triage events / patches |